Spots Global Cancer Trial Database for oropharynx cancer
Every month we try and update this database with for oropharynx cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Outcomes of Prophylactic Swallowing Therapy in Patients Undergoing Definitive Chemoradiation for Head and Neck Cancer | NCT03435471 | Head and Neck C... Oropharynx Canc... | Prophylactic Sw... Clinician-Direc... | 18 Years - | University of Miami | |
| TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | NCT01108042 | Oropharynx Canc... Squamous Cell C... | Taxotere, Cispl... | 18 Years - 80 Years | University of Jena | |
| Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer | NCT06234748 | Oropharynx Canc... HPV-Related Car... | Radiation Platinum based ... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer | NCT01066741 | Oropharynx Canc... Hypopharynx Can... | Homeodent® 1.4% Sodium Bic... | 18 Years - 85 Years | Centre Leon Berard | |
| Pembrolizumab in Combination With CRT for LA-SCCHN | NCT02586207 | Head and Neck C... Squamous Cell C... Oral Cavity Can... Oropharynx Canc... Hypopharynx Can... Larynx Cancer Laryngeal Cance... | pembrolizumab (... Cisplatin Radiation | 18 Years - | Sanford Health | |
| Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae | NCT05757817 | Head and Neck C... Oral Cavity Can... Oropharynx Canc... | Oropharyngeal o... | 18 Years - | Institut Claudius Regaud | |
| Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer | NCT03416153 | Oropharynx Canc... | Carboplatin Radiation Thera... Paclitaxel | 18 Years - | University of Michigan Rogel Cancer Center | |
| Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer | NCT04444869 | Cancer of the H... Oropharynx Canc... HPV Positive Or... Throat Carcinom... | Cisplatin injec... | 18 Years - | University of Missouri-Columbia | |
| IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC | NCT00158678 | Oral Cancer Oropharynx Canc... Hypopharynx Can... | IMRT 75 Gy Conventional ra... concomitant cis... | 18 Years - | Groupe Oncologie Radiotherapie Tete et Cou | |
| Neoadjuvant Chemotherapy and Transoral Robotic Surgery for Oropharyngeal Cancer. | NCT04277858 | Oropharynx Canc... Tonsil Cancer Throat Cancer Base of the Ton... | Docetaxel | 18 Years - 80 Years | McGill University Health Centre/Research Institute of the McGill University Health Centre | |
| E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | NCT05686226 | Cervical Cancer Throat Cancer Oropharynx Canc... Anal Cancer Vulva Cancer Vaginal Cancer Penile Cancer Metastatic Canc... HPV-Related Mal... HPV-Related Car... HPV-Related Cer... HPV-Related Squ... HPV-Related Ade... HPV Positive Or... HPV-Associated ... HPV-Related Ade... HPV-Related End... HPV-Related Ana... HPV-Related Pen... HPV-Related Vul... HPV Positive Re... | E7 TCR-T cells | 18 Years - | Rutgers, The State University of New Jersey | |
| QUantitative Assessment of Swallowing After Radiation (QUASAR) | NCT04359199 | Head and Neck C... Dysphagia Oropharyngeal D... Oropharynx Canc... Oropharynx Squa... | Radiation Thera... Cetuximab Chemotherapy Immunotherapy | 18 Years - | University of California, San Diego | |
| Bitter Taste Receptors in Oropharynx Cancer | NCT05211427 | Oropharynx Canc... | Biopsy | 18 Years - | Technische Universität Dresden | |
| Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia | NCT06276946 | Oropharynx Canc... Head and Neck C... Xerostomia | standard radiot... experimental ra... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Multispectral Imaging to Characterize Patterns of Vascular Supply Within Lymphoepithelial Mucosa in Oropharyngeal Cancer | NCT02365844 | Oropharyngeal C... Oropharynx Canc... | 18 Years - | Stanford University | ||
| Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer | NCT03269344 | Oropharynx Canc... | Gabapentin Placebo Oral Ca... | 18 Years - | Henry Ford Health System | |
| Special Care Patterns for Elderly HNSCC Patients Undergoing Radiotherapy | NCT05337631 | HNSCC Oral Cavity Can... Oropharynx Canc... Hypopharynx Can... Larynx Cancer | 65 Years - | University Hospital Freiburg | ||
| The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors | NCT05798780 | Oral Cavity Can... Oropharynx Canc... Hypopharynx Can... Larynx Cancer | ENHANCE Interve... ENHANCE Interve... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) | NCT05787639 | Oropharynx Canc... | Evorpacept | 18 Years - | University of California, San Diego | |
| Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) | NCT05787639 | Oropharynx Canc... | Evorpacept | 18 Years - | University of California, San Diego | |
| Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer | NCT05698667 | Oropharynx Canc... Oropharynx Neop... Tonsil Cancer Tonsil Neoplasm Tonsil Hypertro... Tonsil Lymphoma Base of Tongue ... Base of Tongue ... | Transoral ultra... Transcervical u... | 18 Years - | Rigshospitalet, Denmark | |
| Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma | NCT03174275 | Carcinoma, Squa... Oral Cancer Oropharynx Canc... Larynx Cancer Lip Cancer Esophageal Canc... | Durvalumab Carboplatin Nab-paclitaxel Cisplatin Surgical resect... IMRT | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer | NCT05388773 | Oropharynx Canc... | therapeutic con... laboratory biom... quality-of-life... intensity-modul... Cisplatin Carboplatin | 18 Years - | University of Pittsburgh | |
| Adaptive Radiotherapy for Head and Neck Cancer | NCT03096808 | Head and Neck C... Paranasal Sinus... Oropharynx Canc... Oral Cavity Can... Nasopharynx Can... Larynx Cancer Hypopharynx Can... | Adaptive Radiot... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | NCT03715946 | Carcinoma, Squa... Oropharynx Squa... | Nivolumab Injec... Radiotherapy (R... | 18 Years - | University of Pittsburgh | |
| Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients | NCT04001413 | HPV Positive Or... Oropharynx Canc... HPV-Related Car... | MEDI0457 Durvalumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC | NCT00162708 | Oropharynx Canc... Oral Cancer Hypopharynx Can... Larynx Cancer | Radiotherapy 62... Radiotherapy 62... CDDP, 5 Fu | 40 Years - 75 Years | Gustave Roussy, Cancer Campus, Grand Paris | |
| Quarterback 2b - Sequential Therapy With Reduced Dose Chemoradiotherapy for HPV Oropharynx Cancer | NCT02945631 | Locally Advance... | PTV56 PTV50.4 | 18 Years - | Icahn School of Medicine at Mount Sinai | |
| Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. | NCT01173692 | Oropharynx Canc... | Minocycline Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | NCT03715946 | Carcinoma, Squa... Oropharynx Squa... | Nivolumab Injec... Radiotherapy (R... | 18 Years - | University of Pittsburgh | |
| Circulating Biomarkers in Oropharyngeal Cancers | NCT05904327 | Oropharynx Squa... Oropharynx Canc... Tonsillar Cance... Base of the Ton... | - | Region Örebro County | ||
| Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx | NCT04667585 | Oropharynx Canc... | De-escalated ra... Standard radiat... 18 fluorodeoxyg... | 18 Years - | Duke University | |
| Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer | NCT00080028 | Head and Neck C... Oropharynx Canc... Larynx Cancer Hypopharynx Can... | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients | NCT03342378 | Squamous Cell C... Oropharynx Canc... | Intensity modul... PET-MRI | 18 Years - | University of Wisconsin, Madison | |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | NCT05307939 | HPV Oropharynx Canc... HPV-Related Car... HPV-Related Mal... HPV Positive Or... | HPV ctDNA Assay MRI Studies EORTC QLQ H&N 3... MDADI-HN COST-FACIT Intensity-Modul... Chemoradiation ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Multispectral Imaging to Characterize Patterns of Vascular Supply Within Lymphoepithelial Mucosa in Oropharyngeal Cancer | NCT02365844 | Oropharyngeal C... Oropharynx Canc... | 18 Years - | Stanford University | ||
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Cell-free Tumor DNA in Head and Neck Cancer Patients | NCT03942380 | Head and Neck C... Head and Neck N... Head and Neck S... Oropharynx Canc... Oropharynx Neop... Oropharynx Carc... Oral Cavity Can... Oral Cancer Oral Neoplasm Larynx Cancer Larynx Carcinom... Larynx Neoplasm Nasopharyngeal ... Nasopharyngeal ... Nasopharynx Neo... Hypopharynx Can... Hypopharynx Neo... Hypopharynx Car... Sinonasal Carci... Thyroid Carcino... Thyroid Cancer Thyroid Neoplas... Salivary Gland ... Salivary Gland ... Salivary Gland ... Sinonasal Cance... Sinonasal Neopl... | Liquid biopsy | 18 Years - | Rigshospitalet, Denmark | |
| Physiological Flow of Liquids in Head and Neck Cancer Patients: A Pilot Study | NCT04112940 | Deglutition Dis... Oropharynx Canc... | Starch-based Th... Xanthan-gum Thi... | 18 Years - 100 Years | University Health Network, Toronto | |
| Outpatient Ultrasound for the Diagnostic Work-up of Oropharynx Cancer | NCT05698667 | Oropharynx Canc... Oropharynx Neop... Tonsil Cancer Tonsil Neoplasm Tonsil Hypertro... Tonsil Lymphoma Base of Tongue ... Base of Tongue ... | Transoral ultra... Transcervical u... | 18 Years - | Rigshospitalet, Denmark | |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | NCT03589339 | Radiotherapy Immunotherapy Microsatellite ... Metastasis From... Squamous Cell C... Metastasis From... Metastatic Rena... Metastasis From... Metastatic Trip... Metastatic NSCL... Metastasis From... | NBTXR3 SABR Nivolumab Pembrolizumab | 18 Years - | Nanobiotix | |
| Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | NCT03383094 | Head and Neck S... Cancer Cancer of Head ... Cancer, Advance... Cancer, Metasta... Tumor Tumor Recurrenc... Tumor Neck Tumor Metastasi... Oral Cancer Oropharyngeal C... Oropharynx Canc... Oropharynx Canc... Oropharynx Canc... Oropharynx Canc... | Pembrolizumab Radiation thera... Cisplatin | 18 Years - | University of California, San Diego | |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | NCT05307939 | HPV Oropharynx Canc... HPV-Related Car... HPV-Related Mal... HPV Positive Or... | HPV ctDNA Assay MRI Studies EORTC QLQ H&N 3... MDADI-HN COST-FACIT Intensity-Modul... Chemoradiation ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx | NCT03418792 | Head and Neck C... Oropharynx Canc... Xerostomia Due ... | Parotid-Sparing... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers | NCT05055206 | Oropharynx Canc... | SPECT-CT | 18 Years - | University Health Network, Toronto | |
| NBTXR3 and Radiation Therapy in Treating Patients With Locally Advanced SCC of the Oral Cavity or Oropharynx | NCT01946867 | Head and Neck C... | NBTXR3 activate... | 65 Years - | Nanobiotix | |
| Multi-Site Trial of Navigation vs Treatment as Usual for Delays in Starting Adjuvant Therapy | NCT05793151 | Head and Neck C... Head and Neck S... Oropharynx Canc... Oral Cavity Can... Larynx Cancer | ENDURE | 18 Years - | Medical University of South Carolina | |
| CaptHPV : Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas | NCT02981862 | Cervical Cancer Vulvar Cancer Anal Cancer Oropharynx Canc... Oral Cavity Can... Penis Cancer | CaptHPV method | 18 Years - | Institut de Cancérologie de Lorraine | |
| Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly | NCT06309225 | Oropharynx Canc... Frailty | Modified dose a... | 65 Years - 99 Years | Baptist MD Anderson Cancer Center, Florida | |
| Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma | NCT05535023 | Squamous Cell C... Oropharynx Canc... Head and Neck C... | SAR444245 Cemiplimab | 18 Years - | M.D. Anderson Cancer Center | |
| Proteome- and Methylation Profiles in Oropharyngeal Cancer | NCT04567082 | Oropharynx Canc... | Examination of ... | 18 Years - | Aalborg University Hospital | |
| Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | NCT03082534 | HNSCC Lip SCC Oral Cavity Can... Oropharynx Canc... Larynx Cancer Hypopharynx Can... Nasopharynx Can... Sinonasal Carci... Cutaneous Squam... Head and Neck N... Head and Neck C... Head and Neck S... | Pembrolizumab, ... | 18 Years - | University of California, San Diego | |
| A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer | NCT04630353 | HPV 16+ Confirm... | HB-201 IV HB-201 IV | 18 Years - | Hookipa Biotech GmbH | |
| Immunological Function After Radiation With Either Proton or Photon Therapy | NCT06016699 | HNSCC Head and Neck C... Oropharynx Canc... Hypopharynx Can... Larynx Cancer | blood draws | 18 Years - | University Medical Center Groningen | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers | NCT05055206 | Oropharynx Canc... | SPECT-CT | 18 Years - | University Health Network, Toronto | |
| A Pilot Study of Acupuncture Treatment for Dysphagia | NCT00797732 | Carcinomas, Squ... Dysphagia | Acupuncture | 18 Years - | Dana-Farber Cancer Institute | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| New Modalities for Detection of Oropharyngeal Cancer | NCT03226613 | Human Papilloma... Oropharynx Canc... Base of Tongue ... Tonsil Cancer | Transcervical O... Oral Rinse Coll... Blood Draw | 21 Years - | Vanderbilt University Medical Center | |
| Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors | NCT04301011 | Solid Tumor Microsatellite ... HPV Positive Or... Cervical Cancer Melanoma (Skin) Cutaneous Squam... Mesothelioma Renal Cell Carc... Oropharynx Canc... | TBio-6517 Pembrolizumab | 18 Years - | Turnstone Biologics, Corp. | |
| NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy | NCT03589339 | Radiotherapy Immunotherapy Microsatellite ... Metastasis From... Squamous Cell C... Metastasis From... Metastatic Rena... Metastasis From... Metastatic Trip... Metastatic NSCL... Metastasis From... | NBTXR3 SABR Nivolumab Pembrolizumab | 18 Years - | Nanobiotix | |
| Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Cancer | NCT03269344 | Oropharynx Canc... | Gabapentin Placebo Oral Ca... | 18 Years - | Henry Ford Health System | |
| Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC | NCT00158652 | Oral Cancer Oropharynx Canc... Hypopharynx Can... Larynx Cancer | Conventional ra... middle accelera... very accelerate... 5FU, Paraplatin | 20 Years - 75 Years | Groupe Oncologie Radiotherapie Tete et Cou | |
| OraTest in Combination With Visual Examination and Visual Examination Alone | NCT00537199 | Head And Neck C... Oropharynx Canc... | Visual Examinat... OraTest | 45 Years - | M.D. Anderson Cancer Center | |
| Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma | NCT04124198 | Oropharynx Canc... Oropharynx Squa... Carcinoma, Squa... Carcinoma Oropharyngeal N... Neoplasms, Squa... Neoplasms, Glan... Neoplasms by Hi... Pharyngeal Neop... Otorhinolaryngo... Head and Neck N... Neoplasms by Si... Otorhinolaryngo... Pharyngeal Dise... Papillomavirus ... Virus Diseases DNA Virus Infec... Tumor Virus Inf... Quality of Life | Intensity-Modul... Cisplatin Nimorazole. Transoral Robot... | 18 Years - | Rigshospitalet, Denmark | |
| Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer | NCT04178174 | Head and Neck C... Oropharynx Canc... Human Papilloma... | SABR boost and ... Standard chemor... | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| Feasibility of Adaptive Radiation Therapy for Human-papilloma Virus-positive Oropharyngeal Cancer Patients on MRIdian Linac | NCT05849142 | Oropharynx Canc... | MRIdian Linac | 18 Years - | University of Miami | |
| Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer | NCT06234748 | Oropharynx Canc... HPV-Related Car... | Radiation Platinum based ... | 18 Years - | University of Michigan Rogel Cancer Center | |
| The ENHANCE Study: Exercise and Nutrition in Head And Neck CancEr Survivors | NCT05798780 | Oral Cavity Can... Oropharynx Canc... Hypopharynx Can... Larynx Cancer | ENHANCE Interve... ENHANCE Interve... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer | NCT03715946 | Carcinoma, Squa... Oropharynx Squa... | Nivolumab Injec... Radiotherapy (R... | 18 Years - | University of Pittsburgh | |
| CaptHPV : Validation of the Method "CaptHPV" for the Diagnosis of Human Papillomavirus Associated Infiltrating Carcinomas | NCT02981862 | Cervical Cancer Vulvar Cancer Anal Cancer Oropharynx Canc... Oral Cavity Can... Penis Cancer | CaptHPV method | 18 Years - | Institut de Cancérologie de Lorraine | |
| Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer | NCT01066741 | Oropharynx Canc... Hypopharynx Can... | Homeodent® 1.4% Sodium Bic... | 18 Years - 85 Years | Centre Leon Berard | |
| Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. | NCT01173692 | Oropharynx Canc... | Minocycline Placebo | 18 Years - | M.D. Anderson Cancer Center | |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | NCT05307939 | HPV Oropharynx Canc... HPV-Related Car... HPV-Related Mal... HPV Positive Or... | HPV ctDNA Assay MRI Studies EORTC QLQ H&N 3... MDADI-HN COST-FACIT Intensity-Modul... Chemoradiation ... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer | NCT02908477 | Oropharynx Canc... | Adjuvant Radiat... Docetaxel Cisplatin | 18 Years - | Mayo Clinic | |
| New Modalities for Detection of Oropharyngeal Cancer | NCT03226613 | Human Papilloma... Oropharynx Canc... Base of Tongue ... Tonsil Cancer | Transcervical O... Oral Rinse Coll... Blood Draw | 21 Years - | Vanderbilt University Medical Center | |
| Physiological Flow of Liquids in Head and Neck Cancer Patients: A Pilot Study | NCT04112940 | Deglutition Dis... Oropharynx Canc... | Starch-based Th... Xanthan-gum Thi... | 18 Years - 100 Years | University Health Network, Toronto | |
| Evaluation of the Benefit of a New Surgical Procedure According to IDEAL Recommendations for ORL Cancer Patients: the External Pudendal Flap Used as a New Free Flap for Oral Cavity/Oropharyngeal Reconstruction to Limit Donor Site Sequelae | NCT05757817 | Head and Neck C... Oral Cavity Can... Oropharynx Canc... | Oropharyngeal o... | 18 Years - | Institut Claudius Regaud | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Oral and Oropharyngeal SCC | NCT00232960 | Oral Cancer Oropharynx Canc... | Radiotherapy 50... | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
